Latest filings (excl ownership)
6-K
RepliCel announces a Letter of Intent for Asset Purchase Agreement
20 Mar 24
6-K
Condensed Consolidated Interim Financial Statements
30 Nov 23
6-K
Condensed Consolidated Interim Financial Statements
24 Oct 23
6-K
Current report (foreign)
19 Oct 23
6-K
RepliCel Provides Default Status Update and Announces Shareholder Approval of Equity Incentive Plan
4 Oct 23
6-K
RepliCel Announces DermaPreciseā¢ Development Milestone, Updates Arbitration Proceedings
13 Sep 23
6-K
Current report (foreign)
7 Sep 23
6-K
Notice of Annual General and Special Meeting of Shareholders
30 Aug 23
6-K
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is appointed Chief Financial Officer
29 Aug 23
6-K
Annual General and Special Meeting
17 Aug 23
6-K
Statement of Executive Compensation
9 Aug 23
6-K
Condensed Consolidated Interim Financial Statements
30 May 23
6-K
RepliCel Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options
18 May 23
20-F
2022 FY
Annual report (foreign)
1 May 23
6-K
RepliCel Announces Shareholder Approval of 10% Rolling Stock Option Plan
21 Mar 23
D
$740.78 k in equity / options / securities to be acquired, sold $740.78 k, 5 investors
16 Mar 23
6-K
RepliCel Announces Settlement of Payment of Dividend on Preferred Shares
23 Feb 23
6-K
RepliCel Life Sciences Announces Intention to Pay Dividend on Preferred Shares
23 Feb 23
D
$9.20 k in equity, sold $9.20 k, 1 investor
7 Feb 23
6-K
Current report (foreign)
1 Feb 23
D
$86.94 k in equity, sold $86.94 k, 2 investors
25 Jan 23
6-K
RepliCel Announces Closing of Non-brokered Private Placement
17 Jan 23
6-K
RepliCel Announces Extension to Non-brokered Private Placement
17 Jan 23
D
$558.84 k in equity / options / securities to be acquired, sold $558.84 k, 2 investors
5 Jan 23
6-K
Current report (foreign)
8 Dec 22
6-K
Condensed Consolidated Interim Financial Statements
29 Nov 22
6-K
Current report (foreign)
25 Oct 22
UPLOAD
Letter from SEC
20 Sep 22
20-F/A
2021 FY
Annual report (foreign) (amended)
12 Sep 22
6-K
RepliCel Announces Non-brokered Private Placement
6 Sep 22
6-K
Condensed Consolidated Interim Financial Statements
6 Sep 22
UPLOAD
Letter from SEC
23 Aug 22
6-K
Current report (foreign)
4 Aug 22
6-K
Current report (foreign)
28 Jul 22
6-K
Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
26 Jul 22
6-K
RepliCel Provides Update on Private Placement
7 Jul 22
6-K
Statement of Executive Compensation
7 Jul 22
6-K
Statement of Executive Compensation
30 Jun 22
20-F
2021 FY
Annual report (foreign)
28 Jun 22
6-K
Replicel Life Sciences Inc. Provides Default Status Update
17 Jun 22
Latest ownership filings
SC 13D/A
Schutte Andrew
20 Apr 23
SC 13D/A
Schutte Andrew
26 Jan 23
SC 13D/A
MACKAY JAMIE MYLES
5 Jan 23
SC 13D
MACKAY JAMIE MYLES
29 Sep 22
SC 13D/A
Schutte Andrew
2 Jun 22
SC 13D/A
MAINPOINTE PHARMACEUTICALS, LLC
21 Dec 21
SC 13D
MAINPOINTE PHARMACEUTICALS, LLC
4 Jun 21
SC 13D/A
Schutte Andrew
17 Sep 20
SC 13D
Replicel Life Sciences Inc.
12 Sep 18